Trials / Completed
CompletedNCT03546205
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function
A Single-dose, Open-label, Parallel-group Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Subjects With Varying Degrees of Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
The purpose of study is to evaluate the pharmacokinetics of a single, subcutaneous dose of JNJ-64565111 in adult participants with varying degrees of renal function including participants with end stage renal disease, requiring hemodialysis, compared with participants with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64565111 | All participants will receive a single SC dose of JNJ-64565111 solution on Day 1. |
Timeline
- Start date
- 2018-06-06
- Primary completion
- 2018-12-17
- Completion
- 2018-12-17
- First posted
- 2018-06-06
- Last updated
- 2025-04-27
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03546205. Inclusion in this directory is not an endorsement.